PTPRZ1 and neoplasm: The downstream VEGF effects via VEGF-PTPRZ interaction are not affected by anti-VEGF drugs, which may explain the resistance developed by certain tumor types (such as glioblastoma) to anti-angiogenic cancer therapies [261].